Ellipses Pharma
Luke Slatford is an experienced operations and IT leader with a strong background in the healthcare and technology sectors. Currently serving as Director of Operations and Head of Digital, Data and Technology at Ellipses Pharma since April 2019, Luke has played a pivotal role in establishing a comprehensive IT framework for a growing oncology clinical development business. Prior experience includes consulting for Seqirus, where Luke contributed to building a global IT organization post-acquisition, and a decade at Takeda, where responsibilities encompassed strategic IT leadership across Europe and Asia, including the integration of corporate acquisitions. Luke's career also includes project management roles at the Department of Corrective Services (NSW) and Bluestone APAC, as well as a technical background with McKinsey & Company and Ford Motor Company.
This person is not in any teams
This person is not in any offices
Ellipses Pharma
Ellipses Pharma is an international drug development company, focused exclusively on the advancement of innovative cancer treatments through the clinic. New treatments for cancer are not progressing fast enough. Ellipses is dedicated to making a difference. Headquartered in London, Ellipses is run by a world class leadership team, overseeing a rapidly growing pipeline of high quality clinical oncology opportunities. Supported by privileged partnerships with leading academic institutions, research bodies, universities, Big Pharma and extensive professional networks, Ellipses Pharma aims to be the most direct route from the research laboratory to patients for cancer treatments. Clinical trials are the route to developing more cancer treatments. All too often they have become overly complex and expensive, slowing down the progress of new discoveries and new treatments for patients. We streamline the clinical trials process that so often inhibits the progress of new potential drugs with one overarching objective - making more treatments available to patients. Ellipses provides a permanent source of capital for the development of cancer assets via a scalable business model, and is able to conduct multiple oncology clinical trials in parallel. Supported by our Scientific Affairs Group which comprises many of the world's leading oncologists, Ellipses is taking a new, ambitious approach to significantly impact the cancer drug development market.